Flibanserin

Description

Flibanserin · CAS 167933-07-5 · C20H21F3N4O. UNII 37JK4STR6Z.

Identification

Computed Descriptors

Physical description & handling notes

• White, to off-white powder
• Insoluble in water
• Sparingly soluble in methanol, ethanol, acetonitrile, toluene; solulble in acetone; freely soluble in chloroform; very soluble in methylene chloride
• Stable under recommended storage conditions.
• Crystals from isopropanol; MP 230-231 °C/Filbanserin hydrochloride/
• SMILES C(F)(F)(F)c1cc(N2CCN(CCN3c4c(cccc4)NC3=O)CC2)ccc1

GHS Hazard Classification

Documented Uses

• Preparation: M. Turconi et al., European Patent Office patent 526434; G. Bietti et al., USA patent 5576318 (1993, 1996 both to Boehringer Ingelheim).
• Flibansetrin is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to: - A co-existing medical or psychiatric condition, - Problems within the relationship, or - The effects of a medication or other drug substance. In Canada, it is approved for the same indication but in women less than 60 years of age.
• Sexual dysfunction affects approximately 50% of women in the United States. Among the various factors contributing to sexual dysfunction in women, hypoactive sexual desire disorder (HSDD) is the most commonly identified cause. HSDD is characterized by limited or absent sexual fantasies or desires, resulting in interpersonal strain or heightened distress, which persist for a minimum of 6 months. The diagnosis of this condition is unrelated to relationship issues, psychiatric or medical conditions, or the effects of
• Flibanserin is a serotonergic antidepressant used to treat hypoactive sexual desire disorder. Flibanserin has been associated with a low rate of minor serum aminotransferase elevations during treatment, but has not been linked to instances of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Milk, Human; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists
• /BOX WARNING/ The use of Addyi in patients with hepatic impairment increases flibanserin concentrations, which can cause severe hypotension and syncope. Therefore, Addyi is contraindicated in patients with hepatic impairment. Inhibitors are contraindicated in patients taking Addyi.

Synonyms

Flibanserin; 167933-07-5; Bimt-17; Addyi; Bimt 17; Ectris; Girosa; BIMT 17 BS; BIMT-17-BS; flibanserina; Flibanserine; 37JK4STR6Z; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one; Female Viagra (Street Name); Female Viagra [Street Name]

Frequently Asked Questions

What are the CAS number and molecular formula of Flibanserin?

CAS 167933-07-5; molecular formula C20H21F3N4O; molecular weight — g/mol.

What other names is Flibanserin known by?

Flibanserin, 167933-07-5, Bimt-17, Addyi, Bimt 17, Ectris.

Is Flibanserin classified as hazardous?

Hazard statements reported: H301, H315, H319, H335.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.